# US 2024/0191257 A1 · Gene Therapy for Retinal Disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0191257 A1
- Document ID: US20240191257A1
- Status: Published application
- Kind: A1
- Application number: 18/553,295
- Filed: 2022-03-30
- Published: 2024-06-13
- Earliest claimed: 2021-03-31
- Assignees: Oxford University Innovation Limited
- Applicants: Oxford University Innovation Limited
- Inventors: Imran H. Yusuf; Robert E. MacLaren; Peter Charbel Issa; Michelle E. McClements
- Web page: https://patentgrep.com/patent/US20240191257A1

## CPC

- C07K 14/47: from mammals
- C12N 15/86: Viral vectors
- A01K 67/0275: Genetically modified vertebrates, e.g. transgenic
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- A61P 27/02: Ophthalmic agents
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- A01K 2217/075: inducing loss of function, i.e. knock out
- A01K 2227/105: Murine
- A01K 2267/035: Animal model for multifactorial diseases
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2830/008: cell type or tissue specific enhancer/promoter combination
- C12N 2830/48: regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
- C12N 2830/50: regulating RNA stability, not being an intron, e.g. poly A signal
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides methods for treating, preventing or reversing retinal degeneration. The methods administering to the subject a vector that expresses a Cadherin-related family member 1 (CDHR1) polypeptide. The invention also provides gene therapy vectors that expresses a CDHR1 polypeptide, host cells that express the gene therapy vectors, and pharmaceutical compositions comprising the gene therapy vector.

## Claims

### Claim 1

A method of treating, preventing or reversing retinal degeneration in a subject in need thereof, the method comprising administering to the subject a vector that expresses a Cadherin-related family member 1 (CDHR1) polypeptide.

### Claim 2

A gene therapy vector that expresses a CDHR1 polypeptide.

### Claim 3 (depends on 1, 2)

The method according to claim 1 or the gene therapy vector according to claim 2, wherein the vector is a viral vector.

### Claim 4 (depends on 3)

The method or gene therapy vector according to claim 3, wherein the viral vector is an adeno-associated virus (AAV) vector.

### Claim 5 (depends on 4)

The method or gene therapy vector according to claim 4, wherein the vector comprises an AAV genome or a derivative thereof.

### Claim 6 (depends on 5)

The method or gene therapy vector according to claim 5, wherein the AAV genome is AAV serotype 2 (AAV2) and/or wherein the capsid is serotype 8 (AAV8).

### Claim 7 (depends on 5)

The method or gene therapy vector according to claim 5, wherein the capsid comprises wildtype AAV8 capsid having the amino acid sequence of SEQ ID NO: 13.

### Claim 8

The method or the gene therapy vector according to any one of the preceding claims, wherein the vector comprises, in a 5′ to 3′ direction:
(a) a 5′ inverted terminal repeat sequence (5′ITR);
(b) a promoter sequence, wherein the promoter is operably linked to a polynucleotide sequence encoding the CDHR1 polypeptide;
(c) a translation initiation sequence;
(d) optionally a chicken beta-actin promoter exon-intron-exon sequence (Ex/In/Ex);
(e) the polynucleotide sequence encoding the CDHR1 polypeptide;
(f) optionally a woodchuck hepatitis post-transcriptional regulatory element (WPRE) having the sequence of SEQ ID NO: 7;
(g) a polyadenylation tail sequence; and
(h) a 3′ inverted terminal repeat sequence (3′ITR).

### Claim 9

The method or the gene therapy vector according to any one of the preceding claims, wherein
(i) the 5′ITR has the sequence of SEQ ID NO: 1;
(ii) expression of the CDHR2 polypeptide is controlled by a human rhodopsin kinase promoter (GRK1);
(iii) the translation initiation sequence comprises the Kozak consensus sequence GCCACC;
(iv) the Ex/In/Ex comprises the sequence of SEQ ID NO: 4;
(v) the CDHR1 polypeptide comprises the amino acid sequence of SEQ ID NO: 6, or a variant thereof having at least 80% sequence identity to SEQ ID NO: 6;
(vi) the WPRE comprises the sequence of SEQ ID NO: 7;
(vii) the polyadenylation tail sequence comprises a bovine growth hormone polyadenylation tail sequence of SEQ ID NO: 8; and/or
(viii) the 5′ITR has the sequence of SEQ ID NO: 9.

### Claim 10

The method or the gene therapy vector according to any one of the preceding claims, wherein the vector comprises a sequence selected from SEQ ID NO: 10, a sequence having at least 80% sequence identity to SEQ ID NO: 10, SEQ ID NO: 12, a sequence having at least 80% sequence identity to SEQ ID NO: 11, SEQ ID NO: 12, and a sequence having at least 80% sequence identity to SEQ ID NO: 12.

### Claim 11 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10)

A host cell that produces the gene therapy vector of any one of claims 2 to 10.

### Claim 12 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10)

A pharmaceutical composition comprising the gene therapy vector according to any one claims 2 to 10, and optionally at least one pharmaceutically acceptable diluent, carrier, or preservative.

### Claim 13

The method, gene therapy vector or pharmaceutical composition according to any one of the preceding claims, wherein the gene therapy vector or pharmaceutical composition is administered or for administration by sub-retinal injection.

### Claim 14 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 12)

The gene therapy vector according to any one of claims 2 to 10 or the pharmaceutical composition of claim 12, for use in a method of treating, preventing or reversing CDHR1-associated retinal degeneration.

### Claim 15 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10)

Use of a gene therapy vector according to any one of claims 2 to 10 in the manufacture of a medicament for of treating, preventing or reversing CDHR1-associated retinal degeneration in a subject.
